Journal article
Early response as assessed by anatomic imaging does not predict failure-free survival among patients with Group III rhabdomyosarcoma: a report from the Children's Oncology Group
European journal of cancer (1990), Vol.50(4), pp.816-823
03/2014
DOI: 10.1016/j.ejca.2013.11.031
PMCID: PMC3944684
PMID: 24361229
Abstract
The prognostic significance of response to induction therapy for rhabdomyosarcoma (RMS) by anatomic imaging [computerised tomographic (CT) or magnetic resonance imaging (MRI) scan] is controversial. We previously reported no relationship between early response and failure-free survival (FFS) on Intergroup Rhabdomyosarcoma Study (IRS)-IV. We repeated the same analysis using a more recent clinical trial as an independent cohort of patients with non-metastatic, initially unresected RMS.
A total of 338 patients enrolled in Children's Oncology Group (COG) study D9803 met the inclusion criteria for this analysis: (1) non-metastatic, initially unresected (Group III); (2) embryonal (ERMS) or alveolar (ARMS) histology; (3) documented protocol week 12 response to induction chemotherapy (excluding progressive disease) based on anatomic imaging (CT/MRI) and (4) documented protocol therapy beyond week 12. Response at week 12 was determined by the treating institution as complete response (CR), partial response (PR) or no response (NR). FFS was estimated using the Kaplan-Meier method and comparisons between patient subsets were made using the log-rank test.
Overall objective response rate (CR+PR) at week 12 of therapy was 85% and was similar between ERMS and ARMS. FFS was similar among all patients with CR, PR or NR (p=0.49). Restricting the analysis to either ERMS or ARMS, there was no difference in FFS by response within either histology subset (p=0.89 and p=0.08, respectively).
These findings provide additional evidence that anatomic imaging to assess early response to therapy among patients with RMS does not predict outcome and has questionable use in tailoring subsequent therapy.
Details
- Title: Subtitle
- Early response as assessed by anatomic imaging does not predict failure-free survival among patients with Group III rhabdomyosarcoma: a report from the Children's Oncology Group
- Creators
- Abby R Rosenberg - Seattle Children's Hospital, Seattle, WA, United States; Fred Hutchinson Cancer Research Center, Seattle, WA, United States; University of Washington, Seattle, WA, United States. Electronic address: abby.rosenberg@seattlechildrens.orgJames R Anderson - University of Nebraska Medical Center, Omaha, NE, United StatesElizabeth Lyden - University of Nebraska Medical Center, Omaha, NE, United StatesDavid A Rodeberg - East Carolina University, Greenville, NC, United StatesSuzanne L Wolden - Memorial Sloan Kettering Cancer Center, New York, NY, United StatesSimon C Kao - The University of Iowa College of Medicine, Iowa City, IA, United StatesDavid M Parham - University of Oklahoma Health Sciences Center, Oklahoma City, OK, United StatesCarola Arndt - Mayo Clinic, Rochester, MN, United StatesDouglas S Hawkins - Seattle Children's Hospital, Seattle, WA, United States; Fred Hutchinson Cancer Research Center, Seattle, WA, United States; University of Washington, Seattle, WA, United States
- Resource Type
- Journal article
- Publication Details
- European journal of cancer (1990), Vol.50(4), pp.816-823
- DOI
- 10.1016/j.ejca.2013.11.031
- PMID
- 24361229
- PMCID
- PMC3944684
- NLM abbreviation
- Eur J Cancer
- ISSN
- 0959-8049
- eISSN
- 1879-0852
- Publisher
- England
- Grant note
- U10 CA098413 / NCI NIH HHS U10 CA98413 / NCI NIH HHS U10 CA180886 / NCI NIH HHS U10CA98543 / NCI NIH HHS L40 CA170049 / NCI NIH HHS U10 CA180899 / NCI NIH HHS U10 CA098543 / NCI NIH HHS
- Language
- English
- Date published
- 03/2014
- Academic Unit
- Radiology; Stead Family Department of Pediatrics
- Record Identifier
- 9984051546802771
Metrics
26 Record Views